Investigational drug · Phase 3
IBI354
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Locally Advanced Unresectable or Metastatic Solid Tumors, Ovarian, Primary Peritoneal.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
4
Any phase or sponsor naming "IBI354"
First trial start
2023
Apr 4, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "IBI354", any sponsor or status.
Conditions studied
As listed on its trial records.
- Locally Advanced Unresectable or Metastatic Solid Tumors
- Ovarian
- Primary Peritoneal
- Fallopian Tube Cancer
- HER2-positive Breast Cancer
Approved drugs for the same conditions: Breast cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "IBI354" as an intervention, largest first.
- Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant TherapyPivotal-lookingRecruiting
Fudan UniversityAcademic, hospital or other
NCT05582499 · 716 participants (planned) · Start Nov 1, 2022 · Primary completion Dec 31, 2027
Drug: Dalpiciclib; Pyrotinib and 30 more · For: Breast Neoplasm; Breast Cancer; Breast Tumors and 7 more
Sites: Shanghai, China
- IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast CancerPivotal-lookingRecruiting
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.Industry
NCT07377643 · 540 participants (planned) · Start Feb 10, 2026 · Primary completion Apr 28, 2028
Drug: Trastuzumab; IBI354 and 3 more · For: HER2-positive Breast Cancer
Sites: Beijing, China
- Study of IBI354 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Ovarian, Primary Peritoneal, or Fallopian Tube CancerPivotal-lookingActive, not recruiting
Innovent Biologics (Suzhou) Co. Ltd.Industry
NCT06834672 · 450 participants (planned) · Start Mar 17, 2025 · Primary completion Dec 28, 2027
Drug: IBI354; paclitaxel/Gemcitabine/Liposomal doxorubicin · For: Ovarian; Primary Peritoneal; Fallopian Tube Cancer
Sites: Chongqing, China
Innovent Biologics (Suzhou) Co. Ltd.Industry
NCT05636215 · 368 participants (planned) · Start Apr 4, 2023 · Primary completion Apr 30, 2025
Drug: IBI354 · For: Locally Advanced Unresectable or Metastatic Solid Tumors
Sites: Randwick, Australia; Sydney, Australia; Sunshine Coast, Australia · 6 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Locally Advanced Unresectable or Metastatic Solid Tumors
- IBI133Phase 21 trial
Innovent Biologics (Suzhou) Co. Ltd. · Locally Advanced Unresectable or Metastatic Solid Tumors
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.